The study will be led by pioneer researcher Raphael Mechoulam of the Hebrew University of Jerusalem
Cannbit Ltd., the Israeli cannabis producer, will soon launch a study to test a cannabis-based treatment for three types of aggressive cancer, Cannbit announced last Thursday in a statement. communicated. The study will be led by cannabis research pioneer Raphael Mechoulam of the Hebrew University of Jerusalem, who chairs the Cannbit Scientific Advisory Committee. Hadassah-Ein Kerem University Hospital and Sheba Medical Center will collaborate on the study.
Mechoulam, a professor of medicinal chemistry at the Hebrew University, was the first person to identify the main psychoactive constituent of cannabis, THC. After his appointment to the company, Cannbit has reached an agreement with all his research and will invest 400000 dollars in the study, plus 2 million additional dollars for a drug sales license.
In return, Cannbit will receive an exclusive commercial license for the drug for the duration of the patent (25 years) and for any other intellectual property generated during the study. Other partners will receive 13% of future revenue generated by the drug or any stage of the search.
The study will involve effective molecules in the fight against melanoma, neuroblastoma and glioblastoma. The technology transfer company of the Hebrew University, Yissum, owns the intellectual property of the results of the preliminary study, which will then be transferred to Cannbit for the duration of the patent.